Anti-Glial Fibrillary Acidic Protein

Anti-Glial Fibrillary Acidic Protein

Chemicon (Millipore)

IgG2a

• Human
• Rat

Western blot: 1:10,000 on rat brain

Optimal working dilutions must be determined by end user.

Positive: Neural tissue or astrocyte culture
Negative: Non-neural tissue or neuronal culture

Purified immunoglobulin. Liquid in 0.02M phosphate buffer, 0.25 M NaCl, pH 7.6 with 0.1% sodium azide.

Maintain at 2-8°C in undiluted aliquots for up to 6 months after date of receipt.

P14136

NM_002055.2

• GFAP
• FLJ45472

GFAP

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant has been described, but its full length sequence has not been determined.

• Western Blotting
• Immunocytochemistry

FUNCTION: SwissProt: P14136 # GFAP, a class-III intermediate filament, is a cell- specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
SIZE: 432 amino acids; 49880 Da
SUBUNIT: Isoform 3 interacts with N-terminus of PSEN1.
SUBCELLULAR LOCATION: Cytoplasm. Note=Associated with intermediate filaments.
DISEASE: SwissProt: P14136 # Defects in GFAP are a cause of Alexander disease [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
SIMILARITY: SwissProt: P14136 ## Belongs to the intermediate filament family.

100 µg

Chemicon

Purified

Mouse

Anti-Glial Fibrillary Acidic Protein

1 mg/mL

Monoclonal Antibody